AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
Key Highlights
- ➤Eric Honroth appointed AngioDynamics (ANGO) CEO and director effective November 2, 2026
- ➤Jim Clemmer retires after ten years as CEO, joining as transition consultant
- ➤Honroth most recently led Getinge’s Life Science business as Global President
- ➤AngioDynamics has no outstanding debt and says its Med Tech segment is high-growth
Expert Statements
Howard Donnelly, AngioDynamics Board Chair
“AngioDynamics enters this transition with real momentum, including a high-growth Med Tech segment, a strong balance sheet with no outstanding debt, and an operational transformation that is delivering.”
Howard Donnelly, AngioDynamics Board Chair
“Eric has done what this moment requires. He has built businesses, driven profitable growth, and managed global operations with responsibility for both revenue and cost structure.”
Howard Donnelly, AngioDynamics Board Chair
“He also builds teams and leads with a genuine commitment to patients, and the Board is confident he is the right leader to deliver long-term value during our next chapter.”
Howard Donnelly, AngioDynamics Board Chair
“On behalf of the Board, I want to thank Jim for his exceptional leadership over the past decade.”
Howard Donnelly, AngioDynamics Board Chair
“Under his guidance, AngioDynamics underwent a successful transformation that sharpened our focus and built a solid foundation for sustainable growth and profitability.”
Howard Donnelly, AngioDynamics Board Chair
“Jim’s dedication to our team, patients, customers, and shareholders has left a lasting mark on the Company, and we are deeply grateful for his many contributions.”
Howard Donnelly, AngioDynamics Board Chair
“We look forward to his continued contributions as a trusted senior advisor.”
Eric Honroth, President and Chief Executive Officer-designate of AngioDynamics
“I am honored to lead AngioDynamics at such an important moment for the Company and grateful for the confidence the Board and Jim have placed in me.”
Eric Honroth, President and Chief Executive Officer-designate of AngioDynamics
“The Company has a differentiated technology portfolio, multiple growth drivers, and an exceptionally talented team.”
Eric Honroth, President and Chief Executive Officer-designate of AngioDynamics
“I look forward to working with employees and customers to build on this foundation and accelerate progress where we see the greatest opportunities to improve patient care and create shareholder value.”
Jim Clemmer, Outgoing President and Chief Executive Officer of AngioDynamics
“It has been the privilege of my career to lead AngioDynamics these past ten years.”
Jim Clemmer, Outgoing President and Chief Executive Officer of AngioDynamics
“Together, we sharpened the Company’s focus, expanded operating capabilities, and positioned the business for its next phase of growth.”
Jim Clemmer, Outgoing President and Chief Executive Officer of AngioDynamics
“I am confident Eric’s experience and leadership make him the right person to carry that work forward, and I look forward to supporting a smooth transition.”
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
Medical Technology Executive Brings More than 20 years of Leadership Experience, Including Cardiovascular, Endovascular and Oncology Markets, with a Track Record of Accelerating Growth and Improving Profitability
Get started
Create a free account to read the full story.